Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia
Marie Sebert,Stéphanie Gachet,Thierry Leblanc,Alix Rousseau,Olivier Bluteau,Rathana Kim,Raouf Ben Abdelali,Flore Sicre de Fontbrune,Loïc Maillard,Carèle Fedronie,Valentine Murigneux,Léa Bellenger,Naira Naouar,Samuel Quentin,Lucie Hernandez,Nadia Vasquez,Mélanie Da Costa,Pedro H Prata,Lise Larcher,Marie de Tersant,Matthieu Duchmann,Anna Raimbault,Franck Trimoreau,Odile Fenneteau,Wendy Cuccuini,Nathalie Gachard,Nathalie Auger,Giulia Tueur,Maud Blanluet,Claude Gazin,Michèle Souyri,Francina Langa Vives,Aaron Mendez-Bermudez,Hélène Lapillonne,Etienne Lengline,Emmanuel Raffoux,Pierre Fenaux,Lionel Adès,Edouard Forcade,Charlotte Jubert,Carine Domenech,Marion Strullu,Bénédicte Bruno,Nimrod Buchbinder,Caroline Thomas,Arnaud Petit,Guy Leverger,Gérard Michel,Marina Cavazzana,Eliane Gluckman,Yves Bertrand,Nicolas Boissel,André Baruchel,Jean-Hugues Dalle,Emmanuelle Clappier,Eric Gilson,Ludovic Deriano,Sylvie Chevret,François Sigaux,Gérard Socié,Dominique Stoppa-Lyonnet,Hugues de Thé,Christophe Antoniewski,Dominique Bluteau,Régis Peffault de Latour,Jean Soulier
DOI: https://doi.org/10.1016/j.stem.2023.01.006
IF: 23.9
2023-02-02
Cell Stem Cell
Abstract:Fanconi anemia (FA) patients experience chromosome instability, yielding hematopoietic stem/progenitor cell (HSPC) exhaustion and predisposition to poor-prognosis myeloid leukemia. Based on a longitudinal cohort of 335 patients, we performed clinical, genomic, and functional studies in 62 patients with clonal evolution. We found a unique pattern of somatic structural variants and mutations that shares features of BRCA-related cancers, the FA-hallmark being unbalanced, microhomology-mediated translocations driving copy-number alterations. Half the patients developed chromosome 1q gain, driving clonal hematopoiesis through MDM4 trisomy downmodulating p53 signaling later followed by secondary acute myeloid lukemia genomic alterations. Functionally, MDM4 triplication conferred greater fitness to murine and human primary FA HSPCs, rescued inflammation-mediated bone marrow failure, and drove clonal dominance in FA mouse models, while targeting MDM4 impaired leukemia cells in vitro and in vivo. Our results identify a linear route toward secondary leukemogenesis whereby early MDM4-driven downregulation of basal p53 activation plays a pivotal role, opening monitoring and therapeutic prospects.